Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of NVCR would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2015) — listing | $12,052 0.7× | $17,545 0.7× |
| Year 6 (2020) | $5,800 0.6× | $8,456 0.6× |
| Year 11 (2025) | $2,485 1.2× | $3,627 1.2× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with NVCR
For illustration only — not investment advice. Past performance is not indicative of future results.